. 2007 Oct;3(5):885–892.

Table 1.

Studies comparing the efficacy of montelukast vs placebo in childhood asthma

Study	Design	Study population	Intervention	Main outcome measures	Conclusions
Bisgaard et al 2005	RCT,	2–5 y (n = 549)	MT (4 or 5 mg)	Asthma	Reduced
Bisgaard et al 2005	DB	intermittent asthma	vs placebo, 12 mo	exacerbation episodes	exacerbation
Becker et al 2004	RCT,	6–14 y (n = 138)	MT (5 mg) vs	% change	Significant
Becker et al 2004	DB	mild persistent asthma	placebo 8 wk	FEV₁	improvement (p = 0.005)
Strauch et al 2003	RCT	6–14 y (n = 25)	MT (5 mg) vs	Sputum ECP,	MT suppressed
Strauch et al 2003		steroid-dependent asthma	placebo 4 wk	sputum Eo count FeNo, Qol	sputum ECP, improved QOL no change in rest of parameters
Knorr et al 2001b	RCT,	2-5 y (n = 689)	MT vs	Clinical	Clinically
Knorr et al 2001b	DB	persistent asthma	placebo, 12 wk	parameters of asthma control, Adverse effects. QOL scores	significant, efficacy well tolerated
Knorr et al 1998	RCT,	6-14 y (n = 336)	MT (5 mg) vs	Morning FEV₁	Significant
Knorr et al 1998	DB	persistent asthma	placebo 8 wk	change	improvement (p < 0.001)

Abbrevations: DB, double-blind; ECP, eosinophilic cationic protein; FeNO, fractional exhaled nitric oxide; RCT, randomized control trial; MT, montelukast; QOL, quality of life.